Please login to the form below
ALK-Abello
This page shows the latest ALK-Abello news and features for those working in and with pharma, biotech and healthcare.
ALK-Abello debuts its birch pollen allergy therapy in Germany
Key market for the new product. Danish drugmaker ALK-Abello has launched its tree pollen immunotherapy Itulazax in Germany, its first market, following its European approval earlier this year. ... Tree pollen allergy is highly prevalent in northern Europe
Latest news
-
Positive mid-stage trial gives Allergy’s investors some welcome relief
There are already immunotherapies on the market for grass pollen allergy - including for example Alk Abello/Merck &Co’s oral Grazax/Grastek product - but these can take months of treatment to
-
Merck gets US green light for allergy immunotherapy
Merck was given the nod for the product in Canada earlier this year and it has been sold by Alk-Abello as Grazax in Europe since 2006. ... The FDA is also reviewing Merck and ALK-Abello's ragweed allergy Ragwitek, which was backed by the agency's
-
FDA backs a brace of allergy immunotherapies
Turning to Grastek, which was originally developed by Danish drugmaker Alk-Abello, the panel recommended approval in people aged five to 65, once again on the proviso that those taking it
-
UK's MHRA reveals advertising lapses
iMed Systems promotes allergy treatment. The first complaint upheld by the UK regulator covers a complaint made by Meda Pharmaceuticals and ALK Abello about iMed's promotion of its injectable pen
-
FDA to review Merck & Co's allergy immunotherapy
Both the ragweed and grass pollen immunotherapies are developed in partnership with Denmark-based firm ALK-Abello and Merck has rights to develop, market and distribute approved products in the US,
More from news
Approximately 4 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Deal Watch July 2016
And Finally, Reality Bites. ALK-Abello has issued a press release announcing that Merck &Co has walked away from the deal agreed in 2007 (with Schering-Plough) for the allergy treatments ... No sales figures have been released by either side, but
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
ALK-Abello appoints Søren Jelert as CFO
He will be based at the company’s headquarters in Denmark. Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees ... ALK.”. Jelert will be based at ALK’s headquarters in
-
Cello Health Consulting expands its UK team
Tarplee has over 30 years of life science industry experience and previously worked for the likes of Adherium, ALK Abello, Sanofi and Abbott.
-
ALK Abelló's John Tarplee joins Adherium
UK. He brings over 30 years of sales and market expansion expertise, most recently in the role of senior vice president at Danish immunotherapy company ALK Abelló where he oversaw its
-
Lars Dreiøe joins Sobi in senior quality and compliance role
Moves to the Swedish rare diseases company from Denmark's ALK. Swedish rare diseases company Sobi has appointed Lars Dreiøe as senior vice president chief quality and compliance officer. ... He will join the firm in January from Danish allergy vaccine
-
ALK Abello appoints UK managing director
Sean Connor joins from Shire. ALK Abello has appointed Sean Connor to the role of UK managing director and director of international markets.
More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
